Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for applications in the life sciences and diagnostic industries in the United States. It offers xMAP technology, an open architecture and multiplexing technology, which allows simultaneous analysis of up to 500 bioassays from a single drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres. The companys xMAP technology is used in various segments of the life sciences industry, which includes the fields of drug discovery and development, clinical diagnostics, genetic analysis, bio-defense, protein analysis, and biomedical research. It operates in two segments, Technology and Assay. The Technology segment offers instruments, such as compact analyzers that integrate fluidics, optics, and digital signal processing, as well as peripheral components; FLEXMAP 3D system for use as a general laboratory instrument in life science research and diagnostics markets; and consumables comprising microspheres and sheath fluid. The Assay segment involves in the development and sale of assays on xMAP technology for use on Luminexs installed base of systems. It offers various assay products, which consists of a combination of chemical and biological reagents, and the companys proprietary bead technology used to perform diagnostic and research assays on samples. Luminex Corporation serves pharmaceutical companies, clinical laboratories, research institutions, and medical institutions. It has a collaboration agreement with Northrop Grumman Corporation. Luminex Corporation was founded in 1995 and is based in Austin, Texas.